Today's News | Note: News feeds may no longer be available for the articles on this page.

Lilly Said to Be Near $1.4 Billion US Settlement on Drug 12:54 PM 1/14/2009
New York Times - United States
Eli Lilly may agree to pay $1.4 billion to settle criminal and civil charges that it illegally marketed Zyprexa for unapproved use in patients vulnerable to its risky side effects. ...

Wyeth Alzeheimer drug moving ahead in Europe 12:24 PM 1/14/2009
Reuters - USA
Wyeth said European regulators are satisfied that its bapineuzumab drug for Alzheimer's disease is suited to move ahead with larger late-stage studies. ...

Merck says study confirms efficacy of Erbitux drug 12:01 PM 1/14/2009
Reuters - USA
Merck KGaA said a Phase II trial provided further evidence that its cancer drug Erbitux was effective against bowel tumors where the cells did not have a mutation of the KRAS gene. ...

US declines to clear Schering schizophrenia drug 7:26 AM 1/14/2009
Reuters - USA
The US FDA declined to approve Schering-Plough's experimental drug Saphris (asenapine) for schizophrenia and bipolar disorder. They need more data, but did not request additional clinical trials. ...

Pfizer will sell off fledgling drugs 5:28 AM 1/14/2009
Boston Globe - United States
Pfizer Inc is hoping to sell some of its drug candidates and is cutting 800 researchers (8 percent of science staffers). Focus shifts to medicines to treat cancer, brain disorders, and pain. ...

Genzyme Sees A Bright Future 5:05 PM 1/13/2009
Forbes - NY,USA
Genzyme expects earnings to rise to about $7 per share by 2011 and plans for 16 drug approvals between 2009 and 2012. ...

Nymox says prostate drug met goal in study 3:03 PM 1/13/2009
Forbes - NY,USA
Nymox Pharmaceutical Corp said a follow up study of its enlarged prostate injection NX-1207 showed the drug was more effective than finasteride. ...

Elan Considers Sale to Raise Funds for Drug Tests 12:03 PM 1/13/2009
Bloomberg - USA
Elan faces concerns about the safety of the multiple sclerosis drug Tysabri. It has to pay back more than $1 billion of debt due in 2011 and pay for the most expensive clinical tests of its drug candidates to treat Alzheimer’s disease. ...

FDA declines to approve OTC heartburn drug: Santarus 7:31 AM 1/13/2009
Reuters - USA
The US FDA refused to approve Schering-Plough Corp's marketing application for the over-the-counter version of its heartburn drug Zegerid by partner Santarus Inc. The FDA needs a few more answers. ...

ZymoGenetics Soars on Bristol-Myers Deal for Hepatitis C Drug 5:24 AM 1/13/2009
Bloomberg - USA
ZymoGenetics Inc up 35 percent in extended trading. Bristol-Myers Squibb Co may pay over $1 billion for the PEG-interferon lambda experimental treatment for the hepatitis C liver virus. ...

US lets drugmakers advise doctors on unapproved uses 4:24 AM 1/13/2009
Reuters - USA
The US FDA guidelines allow manufacturers to distribute medical journal articles describing "off-label" or unapproved uses. ...

Roche Talks to Buy Genentech ‘on Track,’ CFO Says 3:33 AM 1/13/2009
Bloomberg - USA
Roche Holding's CFO said talks with Genentech Inc are "on track". The takeover by drugmaker Roche wouldn’t cause the company to cut its dividend. ...

Financial Disclosures on Drug Studies Found Lacking 2:32 PM 1/12/2009
Bloomberg - USA
Forty two percent of marketing applications approved by the US FDA were missing financial information. One percent of clinical investigators disclosed a financial interest. ...

Drug company EpiCept cuts jobs, new research 1:12 PM 1/12/2009
Forbes - NY,USA
EpiCept Corp is cutting 17 jobs and discontinuing drug research. That will save $5.5 million a year. ...

Wyeth, Santaris reach drug development agreement 9:03 AM 1/12/2009
Forbes - NY,USA
The agreement focuses on Santaris Pharma's Locked Nucleic Acid drug platform with Wyeth responsible for product development and commercialization. ...

<- Day Earlier | Today's News